ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

HYZAAR
Hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

HYZAAR Rx

Generic Name and Formulations:
Losartan potassium, hydrochlorothiazide; 50mg/12.5mg, 100mg/12.5mg, 100mg/25mg; tabs.

Company:
Merck & Co., Inc.

Therapeutic Use:

Indications for HYZAAR:

Hypertension (not for initial therapy unless HTN is severe). To reduce stroke in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients.

Adult:

Initially 50/12.5mg once daily (100/12.5mg if BP not controlled on losartan 100mg alone); may increase after 3 weeks as needed to max 100/25mg daily. HTN with LVH (BP not controlled on losartan alone): initially 50/12.5mg once daily; increase as needed to 100/12.5mg, then to max 100/25mg daily.

Children:

Not established.

Contraindications:

Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.

Boxed Warning:

Fetal toxicity.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting therapy, or reduce initial dose. Hepatic impairment: initial therapy not recommended. Severe renal impairment (CrCl<30mL/min): not established. Severe CHF. Renal artery stenosis. Asthma. SLE. Gout. Diabetes. Postsympathectomy. Acute myopia. Secondary angle-closure glaucoma. Monitor BP, electrolytes, calcium, renal function periodically. Pregnancy (Cat.D). Nursing mothers: not recommended.

Pharmacological Class:

Angiotensin II receptor blocker (ARB) + thiazide diuretic.

Interactions:

See Contraindications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). May increase lithium toxicity (monitor). Orthostatic hypotension with alcohol, other CNS depressants. Adjust antihyperglycemics. Hypokalemia with corticosteroids, ACTH. Potentiates other antihypertensives, skeletal muscle relaxants. Concomitant cholestyramine, colestipol; administer at least 4hrs before or 4–6hrs after resin administration.

Adverse Reactions:

Dizziness, upper respiratory infection, cough, back pain; hypersensitivity reactions, renal impairment, electrolyte abnormalities.

Metabolism:

Hepatic (CYP2C9, 3A4).

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Tabs—30, 90, 1000


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs